Global Blood Therapeutics Inc (NASDAQ:GBT)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - GBT

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - GBT

  • Market Cap$3.472bn
  • SymbolNASDAQ:GBT
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS37890U1088

Company Profile

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.Global Blood Therapeutics Inc is a clinical-stage biopharmaceutical company in the United States. Its major focus lies on developing therapeutics for the treatment of blood-based disorders such as red blood cell sickling.

Latest GBT news

Currently there for this company. Visit our news hub for other news .